Biomarker Accelerator Grant Program
Biomarker Accelerator Grant Program supports researchers validating and translating existing PSP biomarkers to improve diagnosis, disease monitoring, treatment-response assessment and clinical research.
Browse similar grants
Funder: CurePSP
Due Dates: December 15, 2026, 5:00 PM US Eastern Time (LOI) | March 31, 2027, 5:00 PM US Eastern Time (Invited full proposal)
Funding Amounts: Up to $500,000 per award for up to three years; no indirect costs
Summary: Supports translation and validation of existing PSP biomarker discoveries for research and clinical use.
Key Information: Projects must focus exclusively on PSP; exploratory biomarker discovery and new prospective patient cohorts are ineligible.
Description
CurePSP’s Biomarker Accelerator Program supports the next steps needed to move existing progressive supranuclear palsy (PSP) biomarker discoveries into research or clinical settings. Its goal is to improve diagnosis, disease monitoring, treatment-response assessment and clinical research by funding validation and translation rather than initial discovery.
Projects may replicate findings in new cohorts, validate methods, develop standardized assays or tools, or integrate biomarkers across modalities. Eligible modalities include fluid, blood, tissue, imaging, molecular, genetic and digital biomarkers. Diagnostic biomarkers are a priority, but monitoring, prognostic and other contexts of use are welcome when they advance PSP research or care. Proposals involving markers not unique to PSP must make a strong case for their PSP-specific application or integration with other biomarkers.
